SHM Converge Scientific Abstract ePoster Gallery-Effects of Anti-Diabetes Medications on Clinical Outcomes of Covid-19 Patients

Pdf Summary

This retrospective study from the Cleveland Clinic evaluated whether pre-admission diabetes medications affected COVID-19 outcomes in 909 hospitalized patients with diabetes. The medications of interest were metformin, DPP-4 inhibitors (DPP4i), and insulin, with outcomes including ICU admission, need for assisted ventilation, renal insufficiency, and mortality.<br /><br />The cohort had a mean age of 67.1 years, was slightly more male than female, and included a large proportion of Black and White patients. Common comorbid risk factors included obesity, chronic kidney disease, and high comorbidity burden. Medication exposure before admission was documented for at least 90 days.<br /><br />On univariate analysis, metformin was associated with lower mortality (p=0.039), while DPP4i showed no significant association with any outcome. Insulin use was associated with higher rates of ICU admission (p=0.001), need for assisted ventilation (p=0.004), and renal insufficiency (p=0.016).<br /><br />However, after multivariable adjustment for demographic factors, kidney function, diabetes type, HbA1c, smoking, insurance, comorbidity burden, and other medications, these associations were no longer statistically significant for most outcomes. Metformin was not significantly associated with ICU admission, ventilation, or mortality. DPP4i remained neutral across all outcomes. Insulin was independently associated with ICU admission in the adjusted model (odds ratio 1.96, 95% CI 1.40–2.76), but its associations with ventilation and mortality were not significant after adjustment.<br /><br />Overall, the study concluded that metformin did not show a confirmed protective effect after adjustment, DPP4i had no meaningful effect, and insulin use likely reflected greater illness severity or comorbidity rather than a direct harmful effect.

Asset Subtitle

Derrick Obiri - Yeboah

Meta Tag

Author List Cecilia Lansang, Derrick Obiri - Yeboah, James Bena, Keren Zhou, Kevin Pantalone, Lauren Buehler, Mahmoud Alwakeel, Vinni Makin

Category Research

Concept Mortality

Concept Anti-diabetic Medication

Concept Hospitalized COVID-19 Patients

Concept Metformin

Concept DPP-4 Inhibitors

Distinguished Non-Finalist

Presenter Organization Cleveland Clinic

Presenting Author Derrick Obiri - Yeboah

Track Outcomes Research

Keywords

COVID-19

diabetes

metformin

DPP-4 inhibitors

insulin

ICU admission

assisted ventilation

renal insufficiency

mortality

retrospective study

Mortality

Anti-diabetic Medication

Hospitalized COVID-19 Patients

Metformin

DPP-4 Inhibitors